Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-HGFR / c-Met Reference Antibody (Korea RIBB patent anti-cMet) | Login | Anti-HGFR / c-Met Reference Antibody (Korea RIBB patent anti-cMet) | ||||||||||||||||
|
||||||||||||||||||
| Anti-HGFR / c-Met Reference Antibody (Metheresis patent anti-Met) | Login | Anti-HGFR / c-Met Reference Antibody (Metheresis patent anti-Met) | ||||||||||||||||
|
||||||||||||||||||
| Anti-DLL4 Reference Antibody (demcizumab) | Login | Anti-DLL4 Reference Antibody (demcizumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ICAM3 / CD50 Reference Antibody (Forerunner patent anti-ICAM-3) | Login | Anti-ICAM3 / CD50 Reference Antibody (Forerunner patent anti-ICAM-3) | ||||||||||||||||
|
||||||||||||||||||
| Anti-IGF1R / CD221 Reference Antibody (Immunomedics patent anti-IGF-1R) | Login | Anti-IGF1R / CD221 Reference Antibody (Immunomedics patent anti-IGF-1R) | ||||||||||||||||
|
||||||||||||||||||
| Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody (BMS patent anti-Integrin α5β1) | Login | Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody (BMS patent anti-Integrin α5β1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-LAP Reference Antibody (Brigham and Womens anti-LAP) | Login | Anti-LAP Reference Antibody (Brigham and Womens anti-LAP) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MAGEA3 Reference Antibody (CT Atlantic patent anti-MAGE-A3) | Login | Anti-MAGEA3 Reference Antibody (CT Atlantic patent anti-MAGE-A3) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MMP9 Reference Antibody (Yeda patent anti-MMP-9) | Login | Anti-MMP9 Reference Antibody (Yeda patent anti-MMP-9) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MUC16 Reference Antibody (oregovomab-MMAE) | Login | Anti-MUC16 Reference Antibody (oregovomab-MMAE) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MUC17 Reference Antibody (Forerunner patent anti-Muc 17) | Login | Anti-MUC17 Reference Antibody (Forerunner patent anti-Muc 17) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab-MMAE) | Login | Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab-MMAE) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NOTCH1 Reference Antibody (Pfizer patent anti-Notch1) | Login | Anti-NOTCH1 Reference Antibody (Pfizer patent anti-Notch1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NOTCH3 Reference Antibody (Genentech patent anti-Notch3) | Login | Anti-NOTCH3 Reference Antibody (Genentech patent anti-Notch3) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (Peresolomab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (Peresolomab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (UCB patent anti-PD-1) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (UCB patent anti-PD-1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDGFB Reference Antibody (MOR-8457) | Login | Anti-PDGFB Reference Antibody (MOR-8457) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) | Login | Anti-PRAME Reference Antibody (Eureka patent anti-PRAME) | ||||||||||||||||
|
||||||||||||||||||
| Anti-RSPO1 Reference Antibody (Oncomed patent anti-RSPO1) | Login | Anti-RSPO1 Reference Antibody (Oncomed patent anti-RSPO1) | ||||||||||||||||
|
||||||||||||||||||
| Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) | Login | Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) | ||||||||||||||||
|
||||||||||||||||||
| Anti-Siglec-2 / CD22 Reference Antibody (NCI m971) | Login | Anti-Siglec-2 / CD22 Reference Antibody (NCI m971) | ||||||||||||||||
|
||||||||||||||||||
| Anti-Siglec-2 / CD22 Reference Antibody (NCI m972) | Login | Anti-Siglec-2 / CD22 Reference Antibody (NCI m972) | ||||||||||||||||
|
||||||||||||||||||
| Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) | Login | Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TGFb1 Reference Antibody (Genzyme patent anti-TGF-β) | Login | Anti-TGFb1 Reference Antibody (Genzyme patent anti-TGF-β) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TMPRSS2 Reference Antibody (Regeneron patent anti-TMPRSS2 ) | Login | Anti-TMPRSS2 Reference Antibody (Regeneron patent anti-TMPRSS2 ) | ||||||||||||||||
|
||||||||||||||||||


